Envisagenics

Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.

Funding

Seed round

On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.